Sometimes the most instructive lessons in drug development come not from successes, but from programmes that did not reach the finish line. NBE-002, developed by NBE Therapeutics, is one worth studying — not as a failure, but as a case study in the tensions that define antibody-drug conjugate design.

A Bold Concept on Paper

NBE-002 combined two ambitious choices: a highly selective antibody targeting ROR1, a receptor overexpressed in several solid tumours and haematological malignancies, with one of the most cytotoxically potent payloads ever incorporated into an ADC — PNU-159682.

The payload itself is chemically remarkable. PNU-159682 is a next-generation anthracycline derivative, structurally distinct from classical agents like doxorubicin. Its rigid, polycyclic architecture enables extremely efficient DNA intercalation, translating into cytotoxic potency orders of magnitude greater than its parent compound. As a warhead, it looks close to ideal.

The programme entered clinical development with understandably high expectations.

What the Chemistry Tells Us

The trial was terminated early, after enrolling only a small number of patients. No detailed public disclosure of the reasons has been made, to the best of our knowledge. But the chemistry of PNU-159682 itself offers part of the explanation.

Highly potent payloads of this class share a characteristic that cuts both ways: extreme hydrophobicity. And in the context of an ADC, hydrophobicity is not a neutral property.

The consequences are well-documented:

Aggregation. Hydrophobic payloads drive self-association of the conjugate, reducing circulating half-life and introducing batch-to-batch variability that complicates both development and dosing.

Off-target toxicity. Aggregated or unstable ADCs release payload in non-tumour tissues, expanding the toxicity profile and narrowing the window in which the drug can be dosed safely.

A compressed therapeutic index. The combination of potency and poor physicochemical behaviour means the gap between efficacious and toxic doses becomes very small — and clinically unworkable.

The lesson is not that potency is undesirable. It is that potency without physicochemical control is difficult to translate.

What Chemistry Can Do

This is where the story becomes instructive rather than merely cautionary. The field has accumulated a range of strategies that directly address these liabilities, and active research is ongoing across all of them.

Reducing hydrophobicity

The most direct approach is to modify the payload or the conjugate to reduce its tendency to aggregate and partition into hydrophobic environments:

• Incorporation of polar functional groups or ionisable moieties into the payload scaffold
• Hydrophilic linkers — PEGylation and polysarcosine-based spacers have shown meaningful reductions in aggregation propensity
• Payload masking via prodrug strategies, where the active species is only revealed after target-specific activation

Improving conjugate stability and controlling DAR

The drug-to-antibody ratio (DAR) and the site of conjugation are both critical variables — and both are amenable to engineering:

• Site-specific conjugation (engineered cysteines, transglutaminase-based methods) yields more homogeneous conjugates with predictable pharmacokinetics
• DAR optimisation — not always maximising, but finding the value that balances payload delivery and conjugate stability
• Linker design that achieves the right balance between stability in circulation and efficient release at the tumour site

Expanding the therapeutic index

Perhaps the most philosophically interesting question in this space is whether it is worth asking: should the payload be maximally potent? Or would a slightly attenuated, more controllable warhead actually outperform in the clinic?

Beyond that question, additional strategies include:

• Tumour-selective cleavable linkers — enzyme-sensitive (cathepsin, legumain) or pH-sensitive designs that preferentially release payload in the tumour microenvironment
• Dual-payload or synergistic conjugate designs that distribute cytotoxic burden across different mechanisms of action

The Broader Principle

NBE-002 illustrates a fundamental tension in ADC design: the properties that make a payload maximally potent are often the same properties that make an ADC difficult to engineer. Hydrophobicity, rigidity, and high intrinsic cytotoxicity are linked — and they all feed into aggregation risk, instability, and a narrow therapeutic window.

Clinical success is not determined by any single component. It emerges from the interplay between payload chemistry, linker design, and conjugation strategy — and from the willingness to ask whether the most powerful choice is also the most appropriate one.

How Sigutlabs Can Help

At Sigutlabs, this is exactly the kind of challenge we work on. Our focus is synthetic and medicinal chemistry for next-generation ADC components:

• Design and synthesis of complex payloads, including potency-attenuated and prodrug variants
• Linker engineering to tune hydrophobicity, stability, and release kinetics
• Support from concept through to conjugation-ready intermediates

If you are working through similar challenges in ADC development, we would be glad to connect.